This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Changing Diabetes® World Tour

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: September 8, 2011
Last updated: January 18, 2017
Last verified: January 2017
This study is conducted in the Middle East, Northern Africa and Europe. The aim of this study is to contribute to the design of a simple screening strategy for countries in scope, by exploring the association between risk factors and undiagnosed diabetes in a screening study.

Condition Intervention
Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Other: No treatment given

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Changing Diabetes® World Tour a Study on the Association of Risk Factors and the Presence of Undiagnosed Diabetes in the Middle East, Northern Africa and Europe

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • HbA1c (Glycosylated Haemoglobin) level [ Time Frame: measured at the screening visit (only 1 visit during the 2 weeks stay of the bus in each country) ]

Secondary Outcome Measures:
  • Number of subjects with diabetes (type 1 and 2) [ Time Frame: measured at the screening visit (only 1 visit during the 2 weeks stay of the bus in each country) ]
  • The presence of retinopathy [ Time Frame: measured at the screening visit (only 1 visit during the 2 weeks stay of the bus in each country) ]

Enrollment: 8304
Study Start Date: November 2010
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Total study population Other: No treatment given
The screening test includes a combination of a risk assessment questionnaire and biochemical tests.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The Changing Diabetes® World Tour is designed as a mobile screening clinic staying for a minimum of 14 days in each location such as malls, public squares, etc. Subjects included in the study are either actively seeking to be screened, or are invited by subjects in their network already included in the study.

Inclusion Criteria:

  • Informed consent obtained

Exclusion Criteria:

  • Subjects with known diabetes (exception: women with a history of gestational diabetes should not be excluded)
  • Pregnant women or women who have given birth within less than a month
  • Subjects suffering from severe illness
  • Subjects with the inability to read and understand the information given (either due to illiteracy or vision problems) and therefore unable to give an informed consent
  • Subjects with mental impairment
  • Subjects treated with systemic cortico-steroids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01437072

Novo Nordisk Investigational Site
Paco de Arcos, Portugal, 2780-730
Saudi Arabia
Novo Nordisk Investigational Site
Riyadh, Saudi Arabia, 3542
United Arab Emirates
Novo Nordisk Investigational Site
Dubai, United Arab Emirates
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT01437072     History of Changes
Other Study ID Numbers: INS-3934
U1111-1123-4683 ( Other Identifier: WHO )
Study First Received: September 8, 2011
Last Updated: January 18, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 21, 2017